 | Up a level |
Rothschild, Sacha I; Zippelius, Alfred; Eboulet, Eric I; Savic Prince, Spasenija; Betticher, Daniel; Bettini, Adrienne; Früh, Martin; Joerger, Markus; Lardinois, Didier; Gelpke, Hans; Mauti, Laetitia A; Britschgi, Christian; Weder, Walter; Peters, Solange; Mark, Michael; Cathomas, Richard; Ochsenbein, Adrian F; Janthur, Wolf-Dieter; Waibel, Christine; Mach, Nicolas; ... (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of clinical oncology, 39(26), pp. 2872-2880. American Society of Clinical Oncology 10.1200/JCO.21.00276
Nowak, Albina; Angelillo-Scherrer, Anne; Betticher, Daniel; Dickenmann, Michael; Guessous, Idris; Juillerat, Pascal; Korte, Wolfang; Neuner-Jehle, Stefan; Pfister, Otmar; Surbek, Daniel; Battegay, Edouard; Steurer, Johann (2019). Swiss Delphi study on iron deficiency. Swiss medical weekly, 149(w20097), w20097. EMH Schweizerischer Ärzteverlag 10.4414/smw.2019.20097
Kamber, C; Zimmerli, Stefan; Suter, Franziska Marta; Müller, Beatrice Ursula; Mansouri Taleghani, Behrouz; Betticher, Daniel; Zander, T; Pabst, Thomas (2015). Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone marrow transplantation, 50(4), pp. 573-578. Nature Publishing Group 10.1038/bmt.2014.290
Jermann, M.; Jost, L. M.; Taverna, Ch.; Jacky, E.; Honegger, H. P.; Betticher, D. C.; Egli, F.; Kroner, Th.; Stahel, R. A. (2004). Rituximab–EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Annals of oncology, 15(3), pp. 511-516. Oxford University Press 10.1093/annonc/mdh093
Rosell, R.; Gatzemeier, U.; Betticher, D. C.; Keppler, U.; Macha, H. N.; Pirker, R.; Berthet, P.; Breau, J. L.; Lianes, P.; Nicholson, M.; Ardizzoni, A.; Chemaissani, A.; Bogaerts, J.; Gallant, G. (2002). Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of oncology, 13(10), pp. 1539-1549. Oxford University Press 10.1093/annonc/mdf332
Von Rohr, A.; Schmitz, S.-F. H.; Tichelli, A.; Hess, U.; Piguet, D.; Wernli, M.; Frickhofen, N.; Konwalinka, G.; Zulian, G.; Ghielmini, M.; Rufener, B.; Racine, C.; Fey, M. F.; Cerny, T.; Betticher, D.; Tobler, A. (2002). Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology, 13(10), pp. 1641-1649. Oxford University Press 10.1093/annonc/mdf272
Cerny, Thomas; Betticher, Daniel (2000). Non-Hodgkin's lymphoma: Role of high-dose therapy in diffuse large B-cell lymphoma. Annals of oncology, 11(suppl 3), pp. 117-121. Oxford University Press 10.1093/annonc/11.suppl_3.117
Pirnia, Farzaneh; Breuleux, Madlaina; Schneider, Erasmus; Hochmeister, Manfred; Bates, Susan E.; Marti, Andreas; Hotz, Michel A.; Betticher, Daniel C.; Borner, Markus M. (2000). Uncertain Identity of Doxorubicin-Resistant MCF-7 Cell Lines Expressing Mutated p53. Journal of the National Cancer Institute JNCI, 92(18), pp. 1535-1536. Oxford University Press 10.1093/jnci/92.18.1535
Betticher, D. C.; Ratschiller, D.; Hsu Schmitz, S.-F.; Von Rohr, A.; Hess, U.; Zulian, G.; Wernli, M.; Tichelli, A.; Tobler, A.; Fey, M. F.; Cerny, T. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of oncology, 9(7), pp. 721-726. Oxford University Press 10.1023/A:1008273131598
Betticher, Daniel C. (1996). Cyclin D1, another molecule of the year? Annals of oncology, 7(3), pp. 223-225. Oxford University Press 10.1093/oxfordjournals.annonc.a010563
Betticher, D. C.; Zucca, E.; Von Rohr, A.; Egger, T.; Radford, J. A.; Ambrosetti, A.; Bürki, K.; Rufener, B.; Hsu Schmitz, S. F.; Cerny, Thomas (1996). 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma. Annals of oncology, 7(8), pp. 793-799. Oxford University Press 10.1093/oxfordjournals.annonc.a010757
